GlassScriptPhysician profile
Reza Akhtar
NPI 1629195748
$6,474.84
in general payments reported to CMS, 2019-2025
25 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $1,131 · 2021: $895 · 2022: $494 · 2023: $744 · 2024: $900 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906 · Education: $45.58 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,905.58 |
| Education | $45.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,079.95 | 2019-2025 | Exalt Model D, Spyglass, Autotome Rx 49 |
| Abbvie INC. | $719.56 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $618.94 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $447.58 | 2021-2025 | |
| Ambu INC. | $387.96 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.64 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $277.64 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Celgene Corporation | $85.37 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $67.90 | 2022-2023 | Cimzia |
| Genzyme Corporation | $67.70 | 2024 | |
| Becton, Dickinson and Company | $53.34 | 2023 | Phasix Mesh |
| Qol Medical, LLC | $51.71 | 2021-2025 | Sucraid |
| Madrigal Pharmaceuticals | $49.04 | 2025 | Rezdiffra |
| Lilly USA, LLC | $46.12 | 2025 | Omvoh |
| Ardelyx, INC. | $39.55 | 2025 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $37.76 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $36.42 | 2023-2024 | Injectafer |
| Celltrion USA INC. | $35.51 | 2024-2025 | Vegzelma, Zymfentra |
| Mallinckrodt Hospital Products INC. | $15.46 | 2023 | Terlivaz |
| Vivus LLC | $15.35 | 2019 | |
| Intra-Sana Laboratories | $14.53 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Gilead Sciences, INC. | $14.05 | 2019 | |
| Amgen INC. | $12.13 | 2020 | |
| Braintree Laboratories, INC. | $11.99 | 2019 | |
| Phathom Pharmaceuticals, INC. | $8.64 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.